ViAqua Therapeutics is a biotechnology startup that operates in the aquaculture industry, specifically focusing on the prevention of diseases in farmed shrimp. The company has developed an innovative oral delivery platform that uses encapsulated RNA particles to improve the resistance of shrimp and other aquaculture species to diseases. This is a significant breakthrough as there has been no effective method to prevent viral diseases in shrimp, which can wipe out an entire pond within 10 days.

ViAqua's business model revolves around the sale of its proprietary feed, which contains the RNA particles. This feed is sold to shrimp farmers worldwide, who are the primary clients of the company. The company operates in a global market, with the total value of the annual shrimp market being substantial. The market has also seen consistent growth over the past decade, indicating a promising future for the company.

The company's product not only enhances the health of the shrimp, reducing mortality from viral diseases such as White Spot Syndrome Virus (WSSV), but also addresses a significant gap in the aquaculture industry - health management. As the global population grows and the demand for food increases, effective health management in aquaculture is becoming increasingly important. ViAqua's solution offers a proven method of disease prevention, which is a key selling point for the company.

In summary, ViAqua Therapeutics is a promising biotech startup that has developed a unique solution to a significant problem in the aquaculture industry. The company's innovative approach to disease prevention in shrimp farming could potentially revolutionize the industry and contribute to global food security.

Keywords: Biotechnology, Aquaculture, Disease Prevention, Shrimp Farming, Oral Delivery Platform, RNA Particles, Health Management, Global Market, Food Security, Innovation.